Lithium treatment for Cornelia de Lange syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests whether lithium can help people with Cornelia de Lange syndrome (CdLS) who have a confirmed NIPBL gene mutation. It might improve their daily life and overall well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be older than 4 years old
- Body weight should be in the normal range for CdLS based on age and height
- Diagnosis of CdLS must be confirmed by clinical criteria and a NIPBL gene mutation
- Medications must be stable for at least 4 weeks before starting the study
- You need a parent or legal guardian to sign a consent form
- The study drug can be taken as capsules, drops, or mixed with food or drinks to help with swallowing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a supplement-like medicine called N-acetylcysteine (NAC) can reduce repetitive behaviors and self-injurious behaviors in people with Cornelia de Lange syndrome (CdLS). It also checks safety over about 18 weeks at Johns Hopkins Hospital.
This study tests a structured behavior assessment and treatment program for children with Cornelia de Lange syndrome who have challenging behaviors. It may help reduce self-injury, aggression, and disruptive behavior through a plan families can carry out.
This trial tests whether taking lithium for 2 years can improve symptoms in people with a TBR1 gene change that causes neurodevelopmental challenges. It aims to see if lithium is safe and helpful for this condition.
This study tests whether lithium can prevent memory loss or cognitive decline in older adults with mood disorders like depression or bipolar disorder. If you qualify, you would receive lithium treatment and be closely monitored.
This trial tests an experimental drug called PLX-200 for children with certain rare brain diseases. It aims to see if the drug is safe, tolerable, and helpful for slowing the disease.
This Phase 3 trial tests whether N-acetyl-leucine can improve symptoms in people with Niemann-Pick disease type C (NPC). If you qualify, you will be asked to take study medicine and complete symptom and movement tests over time.
Hear when a new Cornelia de Lange Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.